Alan Brochstein
As seen in:
LinkedIn,
MSN,
Forbes,
Seeking Alpha,
Leafly,
Cannabis Business Times,
Our Community Now,
TalkMarkets
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Alan Brochstein
Financial Advisors Should Get to Know Hazel
NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates. Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.
Wny I Am Upgrading Adobe
It's been a rough month for Adobe (ADBE), down 19.6% so far in September, and it's been a tough year for the company too. ADBE has dropped 32.7% in 2026 and appears to be very cheap at a PE ratio that is slightly under 9X. I downgraded it on TalkMarkets on August 26th, and I am upgrading it today. A Look at the Chart Over the past year, ADBE has dropped a massive 34.7%, while Invesco QQQ Trust (QQQ) has increased in price by almost 25%.
Pelorus Capital Is Potentially Perilous
Pelorus Capital, based in Newport Beach, is an investment manager that is privately held. Its website discusses the company, but it never says why it is named Pelorus, which is a navigational tool for mariners. The “About” page discusses its ratings by Egan-Jones and the number of funded loans (73). It also shares a timeline that suggests it was the first dedicated cannabis lender in 2016. In 2025, it launched the Pelour Growth Fund.
Pelorus Capital Is Potentially Perilous
NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates. Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.
Gemalgo: Quantitative AI But Nothing to Do with Jim Simons
NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates. Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.
Unethical Advertisements for Investing Using AI
NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates. Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.
Boston Beer Is A Beaten-Up Buy
May 06, 2026, 1:56 PM ET, , , Summary The Boston Beer Company, Inc. remains a reasonably priced growth stock despite recent earnings-driven pullback and sector-wide headwinds. SAM stock trades at 21.7x 2026 EPS and 8.9x projected adjusted EBITDA, with a strong balance sheet—zero debt and $164 million in cash. 2026 revenue and EPS are expected to decline slightly, but 2027 forecasts show a return to growth with EPS projected to rise 16%.
Verano Is The Best Large MSO Stock
Apr 26, 2026, 8:45 AM ET, Summary Verano Holdings is upgraded to Buy, reflecting improved industry outlook and compelling valuation versus MSO peers. Despite recent revenue and EBITDA declines, VRNO trades at just 3.3x 2026E adjusted EBITDA, with potential upside if 280E taxation is eliminated. Balance sheet risks persist, notably with net debt at $317M and uncertain tax liabilities, but operational improvements and strategic positioning are evident.
Aurora Cannabis: Why I Like This Stock
Apr 24, 2026, 5:27 PM ET, Summary Aurora Cannabis Inc. has transformed into a cannabis-focused company with improving international revenue and margins, while spinning off its Bevo division. ACB's balance sheet now shows net cash of C$46.7 million, achieved through equity sales, and enterprise value trades at just 3.8x projected FY27 adjusted EBITDA. I target a 64% upside for ACB to US$5.58 within a year, based on a 6x FY28 adjusted EBITDA multiple, with the stock trading below tangible book value.
MSOS: Cannabis Investors Should Be Careful With This ETF
Apr 23, 2026, 9:05 AM ET, , , Summary AdvisorShares Pure US Cannabis ETF remains a Strong Sell due to extreme concentration in three names and excessive volatility. Potential cannabis rescheduling could eliminate 280E taxation, boosting net income for operators, but risks remain if the process stalls or fails. MSOS trades at a 7.5x 2026 EV/adj. EBITDA, but this metric understates risk by excluding large tax liabilities, especially for CURLF and TCNNF.
Tilray Brands Is Looking Better
Apr 02, 2026, 2:11 PM ET, , , , , , , Summary Tilray Brands (TLRY) remains a Hold, with valuation near tangible book value and a mixed Q3 showing revenue growth but margin pressure. Strength in cannabis and distribution segments offset weak beverage sales, while international cannabis revenue soared 73% in Q3, now 37% of segment revenue. Adjusted EBITDA guidance for FY26 is $62–$72 million, with consensus FY28 margin expectations at 9.5%, but cash flow remains negative and M&A execution is a risk.
Cannabis Stocks Were Crushed in March
NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates. Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.
SNDL Remains Cheap But Risky
Mar. 15, 2026 9:15 AM ET, , , , , Summary SNDL remains rated hold after a lackluster Q4, with no compelling catalyst to upgrade to buy. SNDL trades at a discount to tangible book value and maintains a debt-free, cash-rich balance sheet, supporting downside protection. Valuation appears fair at 4.3x 2026E adjusted EBITDA, with peer multiples notably higher, but sector-wide challenges persist.
GTI Is Good, but RYM Is Bad
Rythm, Inc. (RYM) reported its Q4 today and filed its 10-K for 2025. I shared here how their Q3 was bad and that it was a horrible cannabis stock in November. Since then, it has plunged 44.5% to $17.10. It is still a horrible cannabis stock in my view. A Look at Q4 The press release pointed to the massive sequential growth in revenue, which was true: Q4 revenue grew 164% from Q3 to $10.7 million, which was up a ton from a year ago (when it was just $18K).
Cannabis Stocks Held Steady
NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates. Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.
Why MJ Is No Longer A Sell (NYSEARCA:MJ)
Alan Brochstein, CFA Investing Group Leader Comment (1) Summary Amplify Alternative Harvest ETF is upgraded from Sell to Hold after a 33% decline, reflecting improved valuation but persistent sector risks. MJ's structure remains highly concentrated, with over half in CNBS and significant exposure to MSOs and Canadian LPs, driving volatility. Key upside catalysts include potential 280E tax elimination and Canadian cultivation tax reform, but regulatory uncertainty remains high.
Big Cannabis Companies Are Set to Report Q4 Financials
The Public Cannabis Company Revenue & Income Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis companies. This update is our first since the middle of August, when we previewed the Q3 Reports. Tracker Rules This data-driven, fact-based tracker will continually update based on new financial filings so that readers can stay up to date. Companies must file with the SEC or SEDAR and be current to be considered for inclusion.
Organigram Global Is Now A Strong Buy (NASDAQ:OGI)
Alan Brochstein, CFA Investing Group Leader Comments Summary Organigram is upgraded to Strong Buy despite Q1 revenue and EBITDA missing estimates, citing long-term value and strategic positioning. OGI trades at a low 7.8x CY26 projected EBITDA and 1.1x tangible book value, reflecting limited downside for a debt-free, legally operating company.
Innovative Industrial: Why I Am Downgrading It (NYSE:IIPR)
Alan Brochstein, CFA Investing Group Leader Comments Summary Innovative Industrial Properties is downgraded from Strong Buy to Hold due to sector and REIT-specific concerns, including the sell-off of the preferred stock. IIPR remains attractively valued, trading below tangible book (0.74x) and at 7x projected AFFO, but tenant financial health and maturing debt are risks. The 15.2% dividend yield is unsustainably high, with the payout exceeding AFFO; a cut may be likely and ultimately beneficial.
Stay on Top of ETFs!
I wrote a piece here in December about my interest in ETFs, concluding that not all ETFs are good. That piece included something about every ETF article that I had published at Seeking Alpha since October 19th. I have published a few more since then: 12/21: 12/25: 01/04: 01/12: The last one was by my new alias at Seeking Alpha, The Intelligent ETF Investor. I continue to publish articles on cannabis stocks primarily with my original Seeking Alpha account, Alan Brochstein, CFA.
Canopy Growth Is Making Big Moves In Its Cannabis Business (NASDAQ:CGC)
Alan Brochstein, CFA Investing Group Leader Comments Summary Canopy Growth remains a hold, supported by a strengthened balance sheet and improved liquidity following recent debt refinancing and equity raises. The pending MTL Cannabis acquisition expands CGC’s Canadian footprint, particularly in Quebec, but offers only modest financial synergies and limited near-term upside.
Why I Am Upgrading SNDL (NASDAQ:SNDL)
Alan Brochstein, CFA Investing Group Leader Comments Summary SNDL Inc. is upgraded from Sell to Hold after a sharp price decline, with valuation now appearing fair and downside seemingly limited. Q3 results were mixed: cannabis revenue grew 14%, but overall margins and operating income declined; free cash flow improved significantly year-over-year. SNDL trades at a deep discount to tangible book value, with a strong balance sheet—C$240.6 million cash, no debt, and C$916 million tangible book.
Cannabis Sales Growth Was Slow in December
NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates. Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.
Why NOBL Could Falter (BATS:NOBL)
Alan Brochstein, CFA Investing Group Leader Comments Summary ProShares S&P 500 Dividend Aristocrats ETF (NOBL) is initiated at Hold, favored over some dividend peers but not top-ranked. NOBL offers strong diversification, equal-weighting, and low sector concentration, with a 0.35% fee and $11.1B AUM across 69 holdings. Recent performance lags the S&P 500 and key dividend ETF peers; NOBL returned 6.8% in 2025 versus SPY’s 17.7%.
Cannabis Stocks Rally in December But End 2025 Down Yet Again
NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates. Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.
Glass House Brands Is Too Expensive (OTCMKTS:GLASF)
Alan Brochstein, CFA Investing Group Leader Comments Summary Glass House Brands (GLASF) is a leading California-based cannabis cultivator with strong operational execution but faces significant valuation concerns. GLASF trades at 9.9x tangible book and 19.3x projected 2026 EBITDA, making it far more expensive than peers like CURLF and GTI. Despite a major ICE raid in July and a challenging 2025 outlook, analysts expect record revenue and EBITDA for GLASF in 2026.
PEY Is Not As Bad As It Looks (NASDAQ:PEY)
Alan Brochstein, CFA Investing Group Leader Comments Summary Invesco High Yield Equity Dividend Achievers ETF (PEY) is rated Hold despite recent underperformance. PEY offers a higher dividend yield and lower technology exposure than major indexes but lags in total returns and has a concentrated portfolio. The ETF's 0.54% expense ratio is high for a passive fund, yet not prohibitive given its unique index and size.
This Falling Cannabis Stock Is Not a Buy
RYTHM, Inc. (RYM), formerly Agrify, is down 1.5% year-to-date, which is way worse than AdvisorShares Pure US Cannabis ETF (MSOS), which has gained 28.1%, and it is a little worse than the Global Cannabis Stock Index, which at 7.21 has gained 4.8%. I last wrote here about RYM on 11/11, reiterating my negative view as I called it a horrible cannabis stock. The stock was then at $31, and it is now at $28.55 as of 12/18's close.
Approach REIT ETFs Cautiously (NYSEARCA:XLRE)
Alan Brochstein, CFA Investing Group Leader Comments Summary I am initiating coverage of Real Estate Select Sector SPDR Fund ETF with a Sell rating due to ongoing sector headwinds. XLRE underperforms equities and bonds, with concentrated exposure and limited diversification compared to VNQ and IYR. Rising rates, inflation risk, and potential economic weakness present significant downside for XLRE, with a projected 15.7% price decline possible.
Cannabis REIT Innovative Industrial Is A Great Option For Investing In The Sector (IIPR)
Alan Brochstein, CFA Investing Group Leader Comments Summary Innovative Industrial Properties remains a Strong Buy due to its deeply discounted valuation and resilient balance sheet, despite sector headwinds. IIPR trades at just 0.74x tangible book and 7.4x AFFO, with a robust 14.3% dividend yield, though the payout exceeds current cash flow. Analyst projections show moderate revenue and FFO growth through 2026–2027, but dividend sustainability and tenant risk remain key concerns.
420 Investor Review Of The Week Ending - 12/19/25
Alan Brochstein, CFA's Blog Investing Group Leader Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors. Comments SAVE 10% ON AN ANNUAL SEEKING ALPHA PREMIUM SUBSCRIPTION News Donald Trump did issue an Executive Order for the Attorney General to work to move cannabis from Schedule I to Schedule III. Michigan reported weak sales in November. Canada sales in October were weak due to a decline in British Columbia.
Now That Cannabis Has Been Rescheduled
Alan J. Brochstein 4 minutes ago 3 min read Yesterday's news was as expected, with President Trump issuing an Executive Order that moves cannabis rescheduling further along. If you ask ChatGPT, you will "learn" that it has been rescheduled: Chat GPT suggests that the action has already rescheduled cannabis, but I don't think that it has. I visited the DEA website, and it is still listed currently as Schedule I. There is no news about the EO at all.
Why I Am Downgrading Green Thumb Industries (GTBIF)
Alan Brochstein, CFA Investing Group Leader Comments Summary Green Thumb Industries is downgraded from Strong Buy to Hold after a significant rally, yet still lags peers in performance. GTI’s strong balance sheet, low net debt, and superior tangible equity make it more resilient than other MSOs, especially if 280E taxation remains. While rescheduling and 280E tax elimination would benefit GTBIF, its relative advantage is smaller than peers due to less exposure and a strong balance sheet.
All About ETFs
The ETF market has gotten massive. What is an ETF? It stands for Exchange-Traded Fund, which was invented in Canada in 1990 and introduced in the U.S. in 1993 with the launch by State Street Global Advisors of the SPDR® S&P 500® ETF (SPY), which represented the overall market as measured by the Standard & Poors 500, a popular large-cap index. Now, there are so many ETFs, and they have expanded their scope beyond broad markets to very narrow ones.
QUAL Is High Quality But Not Timely (BATS:QUAL)
Alan Brochstein, CFA Investing Group Leader Comments Summary iShares MSCI USA Quality Factor ETF (QUAL) earns a Hold rating due to its quality focus and relative resilience versus SPY and VOO. QUAL tracks the MSCI USA Sector Neutral Quality Index, emphasizing high ROE, low earnings variability, and low debt-to-equity across 125 holdings. QUAL has underperformed SPY over recent years but is expected to fare better in market downturns due to lower concentration risk.
Good News For LEEF Brands, But It Is Still a Bad Cannabis Stock
I have written three pieces now on LEEF Brands (LEEEF), which rallied sharply on Friday, rising 20% to $0.189. This gets it back to where it was when I wrote in mid-November that it was a terrible company and a worse stock. When I wrote about it the first time in early August, I explained why I don't view it as a good idea for cannabis investors. The stock, despite surging Friday, is down since then.
Trulieve's Rally Is A Chance To Exit (OTCMKTS:TCNNF)
Alan Brochstein, CFA Investing Group Leader Comments Summary Trulieve (TCNNF) has surged on cannabis rescheduling hopes, but I maintain a strong sell rating and recommend rotating into other cannabis stocks or the sidelines. TCNNF's valuation appears attractive at 4.8x 2025E EBITDA, but significant tax liabilities and aggressive margin assumptions present material downside risk.
420 Investor Review Of The Week Ending - 12/12/25
Alan Brochstein, CFA's Blog Investing Group Leader Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors. Comments SAVE 10% ON AN ANNUAL SEEKING ALPHA PREMIUM SUBSCRIPTION News The big news this week was that Trump appears to be moving forward on cannabis rescheduling.
XLU: Why I Am Upgrading Utilities (NYSEARCA:XLU)
Alan Brochstein, CFA Investing Group Leader Comments Summary I upgrade State Street Utilities Select Sector SPDR ETF from Sell to Hold after a notable price decline and improved valuation metrics. XLU's price-to-book is now 2.3x, P/E is 19.4x, and dividend yield stands at 2.85%. Interest rate trends and recession risk remain key headwinds, but XLU is no longer excessively expensive. I continue to prefer TIPS, especially LTPZ, and see better relative opportunities outside Utilities.
MSOS: How Low It Could Go
I discussed the crash of MSOS again on 11/18, when it closed at $3.16, and it has rebounded to $3.89. Clearly, it is highly volatile! I discussed why it was crashing and how low it could go and shared some good alternatives. Today, I want to discuss the current holdings, the bounce, the acceleration of redemptions of the ETF, and my updated view on the potential downside.
FNDA Is A Good Alternative To Large-Cap ETFs Like VUG
Dec. 07, 2025 9:24 AM ET, , , , , , , , , Summary The Schwab Fundamental U.S. Small Company ETF offers diversified small-cap exposure with fundamental weighting, contrasting VUG's concentrated large-cap technology focus. VUG's top 10 holdings comprise 60.9% of assets, with 63.3% of the ETF in technology, exposing it to significant sector-specific downside risk.
Cannabis Sales Drift Lower in November
NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates. Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.
Tilray Brands Is No Longer A Strong Sell (NASDAQ:TLRY)
Alan Brochstein, CFA Investing Group Leader Comment (1) Summary Tilray Brands, a volatile cannabis stock, has plunged following news that it would be reverse-splitting. The stock's valuation is decent. I am going from Strong Sell to Hold. Darren415/iStock via Getty Images I don't love Tilray Brands, Inc. (TLRY), but I did add it back recently after its reverse-split. Is this a reason to buy it? No, not really, but it is a reason to look into it, which I am doing here.
Why I Am Upgrading Wix.com (NASDAQ:WIX)
Alan Brochstein, CFA Investing Group Leader Comments Summary Wix.com is upgraded to Hold from Sell after a sharp stock decline despite ongoing business growth. WIX's Q3 showed 14% revenue and bookings growth, but margin pressure persists due to AI investments. Balance sheet concerns remain with negative tangible equity, raising questions about continued buybacks amid solid free cash flow.
MSOS Has HEMP THC Prohibition Issues (NYSEARCA:MSOS)
Alan Brochstein, CFA Investing Group Leader Comment (1) Summary I maintain a Strong Sell on AdvisorShares Pure US Cannabis ETF due to excessive volatility and structural portfolio risks. MSOS is heavily concentrated, with 69% exposure to Curaleaf, Green Thumb Industries, and Trulieve, amplifying downside risk. Recent federal hemp THC prohibition threatens growth prospects for key MSOS holdings and may force write-downs.
RSP: A Unique And Compelling ETF, But For Now, It's A Hold (NYSEARCA:RSP)
Alan Brochstein, CFA Investing Group Leader Comments Summary Invesco S&P 500 Equal Weight ETF (RSP) offers a compelling alternative to concentrated large-cap ETFs like SPY and VOO. RSP reduces exposure to mega-cap stocks, providing better diversification and lower valuation risk compared to the traditional S&P 500 index. While RSP has lagged SPY recently, market shifts favoring smaller companies or sector rotation could boost RSP's relative performance.
Why I Now Like Cannabis Stock Organigram Global Again
I have been following the cannabis sector since early 2013, and the stocks are very volatile to say the least. When I started following it, adult-use cannabis sales were legal nowhere. Now, about half of states in the U.S. have adult-use sales, and Canada has had legal adult-use cannabis since 2018.
Sell VTI And Buy VBR To Diversify (NYSEARCA:VBR)
Alan Brochstein, CFA Investing Group Leader Comments Summary Vanguard Total Stock Market Index Fund ETF offers broad exposure but remains heavily weighted to large-cap stocks (technology), limiting true diversification. VTI's performance closely tracks large-cap ETFs like VOO, with both outperforming small-cap benchmarks such as IWM over recent years.
Sell Village Farms And Buy Organigram (NASDAQ:OGI)
Alan Brochstein, CFA Investing Group Leader Comments (42) Summary Organigram upgraded to Buy and Village Farms downgraded to Strong Sell, reflecting shifts in fundamentals and valuation. OGI stands out for its strong balance sheet, strategic partnership with BTI, and potential for margin expansion, despite near-term risks. VFF has surged 356% year-to-date, but concerns over its rapid run-up, lack of guidance, and potential Texas disappointment justify a cautious outlook.
Another Silly Penny Stock
Alan J. Brochstein 4 minutes ago 3 min read I saw a press release the other day that caught my attention. It was released by Protext Mobility (TXTM), and it was very bullish-sounding. The press release, published on 11/19, was a shareholder update. I don't follow TXTM closely. I did pay attention to its predecessor, Plandai Biotechnology, which was PLPL, but it was a total scam that I called out in 2013: It was $0.53 when I published and is now trading near zero.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Alan
Contact Alan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack